# Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity

> **NCT06756061** · PHASE2 · RECRUITING · sponsor: **Byung-Sik Cho** · enrollment: 88 (estimated)

## Conditions studied

- GVHD - Graft-Versus-Host Disease
- Neoplasms
- Haematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Prednisone + Jakavi(ruxolitinib)
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT06756061
- **Lead sponsor:** Byung-Sik Cho
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2027-11-01
- **Final completion:** 2029-08-31
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2025-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06756061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06756061, "Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06756061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*